Abstract
Introduction: Radioprotectors can enhance the efficacy of cancer radiotherapy, but their clinical use remains uncommon. The present study aimed to assess the radioprotective potential of mistletoe extract (commercial name: Abnoba Viscum), a well-known complementary cancer medicine, in zebrafish larvae. Materials and methods: Wild-type AB zebrafish embryos at 4 h-post-fertilization were exposed to 5 Gy 9-MeV electron beam irradiation after being treated for 1 h with 4 mMl/L amifostine or 0.2 mg/ml Abnoba Viscum A, F, M, or Q. Primary endpoints were abnormality-free survival and abnormality-free rates among survivors at 5 days-post-fertilization. Results: The crude abnormality-free survival rates were 33.7%, 49.0%, 38.8%, 43.9%, 38.1%, and 52.6%, whereas abnormality-free rates among survivors were 36.4%, 49.6%, 37.8%, 45.6%, 52.0%, and 62.8% for the control (with no pharmacologic treatment), amifostine, Abnoba Viscum A, F, M, and Q groups, respectively. Abnormality-free survival rates in the amifostine and Abnoba Viscum Q groups were significantly different from those in the control (p =.040 and.012, respectively), with an odds ratio (OR) of 1.90 [95% confidence interval (CI): 1.03–3.51] and 2.20 (95% CI: 1.19–4.08), respectively. Abnormality-free rates among survivors in the amifostine and Abnoba Viscum M and Q groups were significantly different from those in the control group (p =.048,.042, and <.001, respectively), with an OR of 1.79 (95% CI: 1.00–3.20), 1.82 (95% CI: 1.02–3.26), and 2.98 (1.67–5.33), respectively. Conclusion: Abnoba Viscum Q has at least a similar radioprotective effect to that of amifostine. Mistletoe extracts have been clinically applied for a long time and their effectiveness and feasibility have been verified. Abnoba Viscum Q might be a new candidate radioprotectant to enhance cancer radiotherapy efficacy.
| Original language | English |
|---|---|
| Journal | International Journal of Radiation Biology |
| DOIs | |
| Publication status | Published - 2019 Jan 1 |
Fingerprint
Keywords
- mistletoe
- radioprotectant
- radiotherapy
- Zebrafish
ASJC Scopus subject areas
- Radiological and Ultrasound Technology
- Radiology Nuclear Medicine and imaging
Cite this
Radioprotective effects of mistletoe extract in zebrafish embryos in vivo. / Rim, Chai Hong; Koun, Soonil; Park, Hae Chul; Lee, Suk; Kim, Chul Yong.
In: International Journal of Radiation Biology, 01.01.2019.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Radioprotective effects of mistletoe extract in zebrafish embryos in vivo
AU - Rim, Chai Hong
AU - Koun, Soonil
AU - Park, Hae Chul
AU - Lee, Suk
AU - Kim, Chul Yong
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Introduction: Radioprotectors can enhance the efficacy of cancer radiotherapy, but their clinical use remains uncommon. The present study aimed to assess the radioprotective potential of mistletoe extract (commercial name: Abnoba Viscum), a well-known complementary cancer medicine, in zebrafish larvae. Materials and methods: Wild-type AB zebrafish embryos at 4 h-post-fertilization were exposed to 5 Gy 9-MeV electron beam irradiation after being treated for 1 h with 4 mMl/L amifostine or 0.2 mg/ml Abnoba Viscum A, F, M, or Q. Primary endpoints were abnormality-free survival and abnormality-free rates among survivors at 5 days-post-fertilization. Results: The crude abnormality-free survival rates were 33.7%, 49.0%, 38.8%, 43.9%, 38.1%, and 52.6%, whereas abnormality-free rates among survivors were 36.4%, 49.6%, 37.8%, 45.6%, 52.0%, and 62.8% for the control (with no pharmacologic treatment), amifostine, Abnoba Viscum A, F, M, and Q groups, respectively. Abnormality-free survival rates in the amifostine and Abnoba Viscum Q groups were significantly different from those in the control (p =.040 and.012, respectively), with an odds ratio (OR) of 1.90 [95% confidence interval (CI): 1.03–3.51] and 2.20 (95% CI: 1.19–4.08), respectively. Abnormality-free rates among survivors in the amifostine and Abnoba Viscum M and Q groups were significantly different from those in the control group (p =.048,.042, and <.001, respectively), with an OR of 1.79 (95% CI: 1.00–3.20), 1.82 (95% CI: 1.02–3.26), and 2.98 (1.67–5.33), respectively. Conclusion: Abnoba Viscum Q has at least a similar radioprotective effect to that of amifostine. Mistletoe extracts have been clinically applied for a long time and their effectiveness and feasibility have been verified. Abnoba Viscum Q might be a new candidate radioprotectant to enhance cancer radiotherapy efficacy.
AB - Introduction: Radioprotectors can enhance the efficacy of cancer radiotherapy, but their clinical use remains uncommon. The present study aimed to assess the radioprotective potential of mistletoe extract (commercial name: Abnoba Viscum), a well-known complementary cancer medicine, in zebrafish larvae. Materials and methods: Wild-type AB zebrafish embryos at 4 h-post-fertilization were exposed to 5 Gy 9-MeV electron beam irradiation after being treated for 1 h with 4 mMl/L amifostine or 0.2 mg/ml Abnoba Viscum A, F, M, or Q. Primary endpoints were abnormality-free survival and abnormality-free rates among survivors at 5 days-post-fertilization. Results: The crude abnormality-free survival rates were 33.7%, 49.0%, 38.8%, 43.9%, 38.1%, and 52.6%, whereas abnormality-free rates among survivors were 36.4%, 49.6%, 37.8%, 45.6%, 52.0%, and 62.8% for the control (with no pharmacologic treatment), amifostine, Abnoba Viscum A, F, M, and Q groups, respectively. Abnormality-free survival rates in the amifostine and Abnoba Viscum Q groups were significantly different from those in the control (p =.040 and.012, respectively), with an odds ratio (OR) of 1.90 [95% confidence interval (CI): 1.03–3.51] and 2.20 (95% CI: 1.19–4.08), respectively. Abnormality-free rates among survivors in the amifostine and Abnoba Viscum M and Q groups were significantly different from those in the control group (p =.048,.042, and <.001, respectively), with an OR of 1.79 (95% CI: 1.00–3.20), 1.82 (95% CI: 1.02–3.26), and 2.98 (1.67–5.33), respectively. Conclusion: Abnoba Viscum Q has at least a similar radioprotective effect to that of amifostine. Mistletoe extracts have been clinically applied for a long time and their effectiveness and feasibility have been verified. Abnoba Viscum Q might be a new candidate radioprotectant to enhance cancer radiotherapy efficacy.
KW - mistletoe
KW - radioprotectant
KW - radiotherapy
KW - Zebrafish
UR - http://www.scopus.com/inward/record.url?scp=85063694126&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85063694126&partnerID=8YFLogxK
U2 - 10.1080/09553002.2019.1590661
DO - 10.1080/09553002.2019.1590661
M3 - Article
JO - International Journal of Radiation Biology
JF - International Journal of Radiation Biology
SN - 0955-3002
ER -